

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascleto Pharma Inc.**  
**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1672)**

**VOLUNTARY ANNOUNCEMENT**

**PROPOSED AS PRIORITY REVIEW FOR THE  
NEW DRUG APPLICATION OF RAVIDASVIR BY CHINA FOOD  
AND DRUG ADMINISTRATION**

The board of directors of Ascleto Pharma Inc. (the “**Company**”) is pleased to announce that the new drug application (“**NDA**”) of Ravidasvir is on the List of Proposed Priority Review, according to a public notification by China Food and Drug Administration on October 17, 2018.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain NDA approval for, or ultimately market, Ravidasvir successfully.

By Order of the Board of Directors  
**Ascleto Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
October 18, 2018

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Mr. Wei FU, as non-executive Director; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*